Pfizer Inc. (PFE) Shares Bought by Benjamin F. Edwards & Company Inc.
Benjamin F. Edwards & Company Inc. boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 96,317 shares of the biopharmaceutical company’s stock after buying an additional 2,766 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Pfizer were worth $3,439,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in PFE. Mount Vernon Associates Inc. MD boosted its stake in shares of Pfizer by 7.0% in the third quarter. Mount Vernon Associates Inc. MD now owns 33,488 shares of the biopharmaceutical company’s stock valued at $1,196,000 after purchasing an additional 2,200 shares during the period. Xact Kapitalforvaltning AB boosted its stake in shares of Pfizer by 1.1% in the third quarter. Xact Kapitalforvaltning AB now owns 1,090,080 shares of the biopharmaceutical company’s stock valued at $38,916,000 after purchasing an additional 12,056 shares during the period. Nottingham Advisors Inc. purchased a new position in shares of Pfizer in the third quarter valued at approximately $224,000. Personal Capital Advisors Corp boosted its stake in shares of Pfizer by 4.3% in the third quarter. Personal Capital Advisors Corp now owns 887,956 shares of the biopharmaceutical company’s stock valued at $31,700,000 after purchasing an additional 36,318 shares during the period. Finally, Northpointe Capital LLC boosted its stake in shares of Pfizer by 4.7% in the third quarter. Northpointe Capital LLC now owns 152,337 shares of the biopharmaceutical company’s stock valued at $5,438,000 after purchasing an additional 6,793 shares during the period. 69.75% of the stock is owned by institutional investors.
In related news, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. Insiders sold a total of 36,800 shares of company stock worth $1,327,248 over the last ninety days. Corporate insiders own 0.06% of the company’s stock.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the company posted $0.61 EPS. analysts predict that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
Pfizer declared that its board has authorized a share repurchase plan on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.74%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s payout ratio is presently 78.53%.
PFE has been the subject of several recent research reports. Jefferies Group set a $37.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Monday, September 18th. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research note on Wednesday. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Goldman Sachs Group set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, November 1st. Finally, BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Friday, December 15th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company. Pfizer has a consensus rating of “Buy” and an average target price of $38.77.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.